



## **CryoLife, Inc. Introduces Heart Valve Warranty**

April 19, 1999

ATLANTA--(BUSINESS WIRE)--April 19, 1999--CryoLife, Inc. (NYSE:CRY), the leader in the development and commercialization of living human tissue implantable devices and a manufacturer and distributor of stentless heart valves and surgical adhesives, today announced that it has implemented an allograft valve warranty program. The program, which applies to heart valves implanted after April 15, 1999, includes a ten-year limited warranty against problems due to structural deterioration and a lifetime limited warranty for freedom from endocarditis and thromboembolic events.

Steven G. Anderson, President and Chief Executive Officer of CryoLife, said, "To our knowledge, this lifetime limited warranty on heart valves is the first such warranty in the heart valve replacement business, and we believe that it clearly demonstrates that our cryopreserved heart valves should be recognized as the gold standard in our industry. The lifetime warranty highlights our confidence in our cryopreservation process for physicians and patients. Clinical data recently presented at the American College of Cardiology and historical published data indicate that over 90% of the CryoLife heart valves implanted are free from structural deterioration at ten years. These data clearly indicate the absence of valve related endocarditis and thromboembolic events in CryoLife's cryopreserved heart valves."

Founded in 1984, CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular, and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive, CE marked in the European Union for use in vascular and pulmonary sealing and repair, is distributed throughout Europe. The Company also manufactures CryoLife-O'Brien(R) and CryoLife-Ross(TM) stentless porcine heart valves which are distributed within the European Community.

Statements made in this press release which look forward in time involve risks and uncertainties and are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such risks and uncertainties include the possibility of improper implantation of allograft valves by surgeons, the potential impact of a patient's preexisting endocarditis or other abnormalities, the potential impact of an allograft recipient's intravenous drug use or other introduction of bacteria into the recipient's bloodstream, changes in economic cycles, competition from other companies, changes in laws and governmental regulations applicable to the Company and other risk factors detailed in the Company's Securities and Exchange Commission filings, including the Company's Prospectus dated March 30, 1998, contained in its Registration Statement on Form S-3 (No. 333-46545.)

Editor's Note: CryoLife Customer Service may be accessed by telephone: 1-800-438-8285 (U.S. and Canada) 1-770-419-3355 (International) 1-770-590-3753 (International fax) E-mail: [customerservice@cryolife.com](mailto:customerservice@cryolife.com)

For additional information about the Company, visit CryoLife's web site: <http://www.cryolife.com>

--30--

CONTACT: CryoLife Inc., Atlanta  
Roy Vogeltanz, 800/438-8285